TABLE 5.
Prevalence of baseline substitutions among DAA-experienced GT1b-infected patients
| Target | Baseline substitution(s)a | % of patients with baseline substitution(s) (no. of patients with baseline substitution[s]/total no. of DAA-experienced GT1b-infected patients sequenced) |
|||
|---|---|---|---|---|---|
| Without cirrhosis |
With compensated cirrhosis (PI experienced and NS5A inhibitor experienced) | Total | |||
| PI experienced and NS5A inhibitor naive | PI experienced and NS5A inhibitor experienced | ||||
| NS3 | Y56F | 24.0 (6/25) | 19.4 (6/31) | ||
| Q80K/L/R | 50.0 (1/2) | 32.0 (8/25) | 50.0 (2/4) | 35.5 (11/31) | |
| D168E/T/V | 52.0 (13/25) | 50.0 (2/4) | 48.4 (15/31) | ||
| Any | 50.0 (1/2) | 72.0 (18/25) | 75.0 (3/4) | 71.0 (22/31) | |
| Multiple | (0/2) | 32.0 (8/25) | 25.0 (1/4) | 29.0 (9/31) | |
| NS5A | Q24K | 50.0 (1/2) | 26.9 (7/26) | 25.0 (8/32) | |
| L28I/M/T/V | 50.0 (1/2) | 26.9 (7/26) | 25.0 (8/32) | ||
| R30H/L/M/Q | 50.0 (1/2) | 38.5 (10/26) | 34.4 (11/32) | ||
| L31F/I/M/V | 88.5 (23/26) | 75.0 (3/4) | 81.3 (26/32) | ||
| P32deletion | 3.8 (1/26) | 25.0 (1/4) | 6.3 (2/32) | ||
| P58L | 50.0 (1/2) | 3.8 (1/26) | 6.3 (2/32) | ||
| A92K/T | 50.0 (1/2) | 15.4 (4/26) | 15.6 (5/32) | ||
| Y93F/S | 7.7 (2/26) | 6.3 (2/32) | |||
| Y93H | 61.5 (16/26) | 75.0 (3/4) | 59.4 (19/32) | ||
| Any | 100 (2/2) | 96.2 (25/26) | 100 (4/4) | 96.9 (31/32) | |
| Multiple | 50.0 (1/2) | 88.5 (23/26) | 75.0 (3/4) | 84.4 (27/32) | |
a
Baseline substitutions at amino acid positions important for the inhibitor class, positions 36, 43, 54, 55, 56, 80, 155, 156, and 168 in NS3 and positions 24, 28, 30, 31, 32, 58, 92, and 93 in NS5A, at a 15% detection threshold, were included in the analysis. Multiple indicates patients with 2 or more baseline substitutions.